First‑Line ICI + VEGFR‑TKI Combination Therapy for IMDC Intermediate‑Risk Metastatic Clear‑Cell RCC

Guideline Recommendations

• The European Association of Urology (2022) and ESMO (2024) endorse three immune‑checkpoint inhibitor (ICI) + VEGFR‑TKI regimens—pembrolizumab + axitinib, nivolumab + cabozantinib, and pembrolizumab + lenvatinib—as the preferred first‑line options for patients with IMDC intermediate‑risk metastatic clear‑cell RCC (Level 1b evidence)【1】【2】【3】【4】.

Efficacy of Specific Regimens

These efficacy figures are derived from pivotal phase III trials and are supported by the cited literature【4】【5】【6】【7】.

Safety and Dose‑Modification Profiles

• Pembrolizumab + lenvatinib required dose reductions in ≈ 68.8 % of patients, whereas nivolumab + cabozantinib required reductions in ≈ 56.3 % of patients; pembrolizumab + axitinib demonstrated a more manageable toxicity profile with fewer dose adjustments【6】【5】【7】.
• Across all three ICI + VEGFR‑TKI trials, 56–69 % of participants needed VEGFR‑TKI dose reductions, yet efficacy was preserved, indicating that dose modification does not compromise clinical benefit【6】【5】【7】.

Treatment Selection Algorithm

• Eligibility for ICI – Patients with active autoimmune disease requiring systemic immunosuppression, uncontrolled brain metastases, or absolute contraindications to immunotherapy are excluded from ICI‑based regimens【5】.
• If ICI‑eligible, choose among the three ICI + VEGFR‑TKI combinations, guided by toxicity considerations, bone‑metastasis activity (cabozantinib has demonstrated activity in bone lesions), and hepatic involvement (all three regimens are appropriate but require liver‑function monitoring)【1】【3】.
• If ICI‑contraindicated, cabozantinib monotherapy is recommended as the preferred single‑agent TKI for intermediate‑risk disease (Level 2a evidence)【1】【2】.

Alternative ICI Combination

• Nivolumab + ipilimumab remains an option for intermediate‑ and poor‑risk disease, showing an overall‑survival hazard ratio of 0.63 in this population (Level 1b evidence)【1】【2】.

Practical Treatment Considerations

• PD‑L1 testing is not required; ICI‑based combinations are recommended irrespective of PD‑L1 status, and therapy should not be delayed for biomarker assessment【3】.
• Treatment duration – PD‑1 inhibitors are continued for up to 2 years or until disease progression; VEGFR‑TKIs are maintained until progression or unacceptable toxicity【3】【4】.

Common Pitfalls

• Avoid using single‑agent TKIs when ICI‑based combinations are feasible, as they are associated with inferior overall‑survival outcomes【1】【7】【3】.
• Do not perform indirect comparisons among the three ICI + VEGFR‑TKI regimens to declare a “best” option; head‑to‑head data are lacking and guidelines state that no single combination is preferred【2】【7】.

First-Line Treatment Options for Advanced Clear Cell Renal Cell Carcinoma

Introduction to First-Line Treatment

• The American Society of Clinical Oncology recommends that pembrolizumab is not used as monotherapy in the first-line setting for advanced clear cell RCC, but rather in combination with axitinib or lenvatinib 8, 9, 10

Clarifying the Confusion: Adjuvant vs. Advanced Disease Settings

• The European Society for Medical Oncology notes that pembrolizumab monotherapy is FDA-approved for adjuvant treatment after surgery in patients at high risk of recurrence, but in the advanced/metastatic setting, pembrolizumab is only used in combination with VEGFR TKIs 11, 8, 9, 10

First-Line Treatment Combinations for Advanced Clear Cell RCC

• The National Comprehensive Cancer Network recommends ICI-based combinations with VEGFR TKIs, with Level I, A evidence across all risk groups, including pembrolizumab + axitinib, lenvatinib + pembrolizumab, and cabozantinib + nivolumab 8, 9, 10, 12, 13
• The American Society of Clinical Oncology states that pembrolizumab + axitinib has an OS HR of 0.68 and PFS HR of 0.71, with an estimated OS gain of 16.8 months 9, 12
• The European Society for Medical Oncology notes that lenvatinib + pembrolizumab has an OS HR of 0.66 and PFS HR of 0.39, with a PFS gain of 14.7 months and OS gain of 8.8% at 2 years 8, 9, 12, 13
• The National Comprehensive Cancer Network recommends cabozantinib + nivolumab, with an OS HR of 0.60 and PFS HR of 0.51, and a PFS gain of 8.3 months and OS gain of 10.1% at 1 year 8, 13, 14

Alternative Single-Agent TKI Options

• The American Society of Clinical Oncology recommends single-agent VEGFR TKIs, such as sunitinib, pazopanib, and cabozantinib, as alternatives when immunotherapy cannot be given 8, 10, 15
• The European Society for Medical Oncology notes that sunitinib has a Category 2A recommendation across all risk groups, with superior PFS and OS versus interferon-alpha 15, 14
• The National Comprehensive Cancer Network recommends pazopanib, with comparable efficacy to sunitinib but a superior quality of life profile 15, 14

Critical Treatment Selection Algorithm

• The American Society of Clinical Oncology recommends classifying patients as favorable, intermediate, or poor risk, and evaluating for contraindications to immunotherapy 15, 14
• The European Society for Medical Oncology states that if ICI-eligible, intermediate/poor-risk patients should be considered for nivolumab + ipilimumab or any of the three VEGFR TKI + PD-1 inhibitor combinations 9, 16, 14
• The National Comprehensive Cancer Network recommends that if ICI-contraindicated, intermediate/poor-risk patients should receive cabozantinib monotherapy, and favorable-risk patients should receive sunitinib or pazopanib 10, 15, 14

Important Safety Considerations

• The American Society of Clinical Oncology notes that nivolumab + ipilimumab probably increases SAE risk to 57%, with 35% requiring high-dose steroids and 22% experiencing treatment discontinuation 14
• The European Society for Medical Oncology states that pazopanib requires monitoring for hepatotoxicity, with 30% grade 3 ALT elevation rates 14